CDKN2A and cutaneous melanoma: Although many of these mutations were previously characterized in skin melanoma (e.g., BRAF, NRAS, TP53, PPP6C, CDKN2A, RAC1, etc.)[3, 34], to our knowledge, this is the first report that appreciates them in association with tumors of different cytolytic activity.